A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 45, Issue 2, 2015, Pages 395-405

  Remington, Ruth ^a,b   Bechtel, Cynthia ^b   Larsen, David ^c   Samar, Annemarie ^b,d   Doshanjh, Laura ^f   Fishman, Paul ^e   Luo, Yuan ^e,g   Smyers, Kathleen ^a   Page, Robert ^b   Morrell, Christopher ^f   Shea, Thomas B ^a  

^a University of Massachusetts Lowell   (United States)

^b FRAMINGHAM STATE UNIVERSITY   (United States)

^c Advanced Memory Dynamics   (United States)

^d WORCESTER STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f LOYOLA UNIVERSITY MARYLAND   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Acetyl L carnitine; Alzheimer's disease; B vitamins; behavioral difficulties; cognitive decline; N acetyl cysteine; nutrition; S adenosyl methionine; supplement; vitamin E

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; CYANOCOBALAMIN; FOLIC ACID; LEVACECARNINE; NUTRACEUTICAL; PLACEBO; S ADENOSYLMETHIONINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CAREGIVER; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEMENTIA RATING SCALE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MOOD; MOOD DISORDER; MULTICENTER STUDY; NUTRITION; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; CLINICAL TRIAL; COGNITION DISORDERS; COHORT ANALYSIS; COMPLICATION; CONTROLLED STUDY; DIET THERAPY; FEMALE; MALE; MIDDLE AGED; MOOD DISORDERS; PSYCHOLOGY; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; ALZHEIMER DISEASE; CAREGIVERS; COGNITION DISORDERS; COHORT STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; TIME FACTORS; VITAMIN B 12;

EID: 84925365854     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142499     Document Type: Article

References (38)

1. Naylor MD, Karlawish JH, Arnold SE, Khachaturian AS, Khachaturian ZS, Lee VM, Baumgart M, Banerjee S, Beck C, Blennow K, Brookmeyer R, Brunden KR, Buckwalter KC, Comer M, Covinsky K, Feinberg LF, Frisoni G, Green C, Guimaraes RM, Gwyther LP, Hefti FF, Hutton M, Kawas C, Kent DM, Kuller L, Langa KM, Mahley RW, Maslow K, Masters CL, Meier DE, Neumann PJ, Paul SM, Petersen RC, Sager MA, Sano M, Schenk D, Soares H, Sperling RA, Stahl SM, van Deerlin V, Stern Y, Weir D, Wolk DA, Trojanowski JQ (2004) Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit. Alzheimers Dement 8, 445-452.
2. Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M (2002) The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinical stages, mild cognitive impairment, and dementia. Rev Neurol (Paris) 168, 471-482.
3. Selkoe DJ (2012) Preventing Alzheimer's disease. Science 337, 1488-1492.
4. Shea TB, Rogers E, Remington R (2012) Nutrition and dementia: Are we asking the right questions? J Alzheimers Dis 28, 423-431.
5. Morris MC, Tangney CC (2011) A potential design flaw of randomized trials of vitamin supplements. JAMA 305, 1348-1349.
6. Chan A, Paskavitz J, Remington R, Shea TB (2008) Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: A one-year open-label pilot study with a 16-month extension. Am J Alz Dis Other Demen 23, 571-585.
7. Remington R, Chan A, Shea TB (2009) Efficacy of a vitamin/nutraceutical formulation for moderate to late-stage Alzheimer's disease: A placebo-controlled pilot study. Am J Alz Dis Other Demen 24, 27-33.
8. Chan A, Lepore A, Kotoya E, Zemianek J, Remington R, Shea TB (2010) Efficacy of a vitamin/nutraceutical formulation on cognitive speed and recall in adults with no known or suspected dementia. J Nutri Health Aging 14, 224-230.
9. Mischoulon D, Fava M (2002) Role of S-adenosyl-L methionine in the treatment of depression: A review of the evidence. Am J Clin Nutr 76, 1158S-1161S.
10. Royall DR, Cordes JA, Polk M (1998) CLOX: An executive clock drawing test. J Neurol Neurosurg Psychiatry 64, 588-594.
11. Monsch AU, Bondi MW, Salmon DP, Butters N, Thal LJ, Hansen LA, Wiederholt WC, Cahn DA, Klauber MR (1995) Clinical validity of the Mattis Dementia Rating Scale in detecting Dementia of the Alzheimer type. A double cross-validation and application to a community-dwelling sample. Arch Neurol 52, 899-904.
12. Cummings JL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 48, S10-S16.
13. GalaskoD, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11, S33-S39.
14. Cohen J (1992) A power primer. Psychol Bull 112, 155-159.
15. Jurica, PJ, Leitten, CL, Mattis S. (2001) DRS-2 Dementia Rating Scale Professional Manual. PAR, Lutz, FL.
16. Perneczkzy P, Wagenpfeil S, Komossa K, Grimmer T, Deihl j, Kurz A (2006) Mapping scores onto stages: Mini-Mental State Examination and Clinical Dementia Rating. Am J Geriatr Psychiat 14, 139-144.
17. Fauth EB, Gibbons A (2013) Which behavioral and psychological symptoms of dementia are the most problematic?Variability by prevalence, intensity, distress ratings, and associations with caregiver depressive symptoms. Int J Geriatr Psychiatry 29, 263-271.
18. CortesF, NourhashémiF, GuérinO, CantetC, Gillette-GuyonnetS, AndrieuS, OussetPJ, VellasB, Group REAL-FR (2008) Prognosis of Alzheimer's disease today: A two-year prospective study in 686 patients from the REAL-FR Study. Alzheimers Dement 4, 22-29.
19. Johannsen P, Salmon E, Hampel H, Xu Y, Richardson S, Qvitzau S, Schindler R, Study AWARE, Group (2006) Assessing therapeutic efficacy in a progressive disease: A study of donepezil in Alzheimer's disease. CNS Drugs 20, 311-325.
20. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA 311, 33-44.
21. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative, Study (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 289, 2819-2826.
22. Royall DR (2014) Towards an aging-specific cognitive phenotype: The Freedom House Study. Exp Aging Res 40, 245-265.
23. Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L (2014) Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. J Alzheimers Dis 41, 615-631.
24. Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, Waichunas D, Bumgarner L, Bourdette D, Silbert L, Kaye J. (2014) A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. J Alzheimers Dis 38, 111-120.
25. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T, Alzheimer's DiseaseWorking, Group (2010) Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 6, 39-53.
26. Ito K, Corrigan B, Romero K, Anziano R, Neville J, Stephenson D, Lalonde R (2013) Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database. J Alzheimers Dis 37, 173-183.
27. Chan A, Shea TB (2007) Folate deprivation increases presenilin expression, gamma-secretase activity and Abeta levels in murine brain: Potentiation by ApoE deficiency and alleviation by dietary S-adenosyl methionine. J Neurochem 102, 753-760.
28. Chan A, SheaTB(2007) Improved cognitive performance and decreased aggression in normal and ApoE4 mice following dietary supplementation with N-acetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine. Neuromol Med 9, 264-269.
29. Chan A, Tchantchou F, Rogers E, Shea TB (2009) Dietary deficiency differentially regulates presenilin expression, gamma-secretase activity and Abeta levels as a function of ApoE genotype: Role of S-adenosyl methionine. J Neurochem 110, 831-836.
30. Chan A, Tchantchou F, Rogers E, Shea TB. (2009) Tau phosphorylation is differentially regulated by dietary deficiency as a function of ApoE genotype: Role of S-adenosyl methionine. J Alzheimers Dis 17, 483-487.
31. Fuso A, Scarpa S (2011) One-carbon metabolism and Alzheimer's disease: Is it all a methylation matter? Neurobiol Aging 32, 1192-1195.
32. Lee S, Lemere C, Frost J, Shea TB (2011) Dietary supplementation with S-adenosyl methionine delayed Abeta and tau pathology in 3xTg-AD mice. J Alzheimers Dis 28, 423-431.
33. Shea TB, Chan A (2008) S-adenosyl methionine: A natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer's disease. J Alzheimers Dis 13, 67-70.
34. Moustafa AA, Hewedi DH, Eissa AM, Myers CE, Sadek HA (2012) The relationship between associative learning, transfer generalization, and homocysteine levels in mild cognitive impairment. PLoS One 7, e46496.
35. PuertasMC, Martínez-MartosJM, CoboMP, CarreraMP, MayasMD, Ramírez-ExpósitoMJ (2012) Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia. Exp Gerontol 47, 625-630.
36. SalaI, Belén Sánchez-SaudinósM, Molina-PorcelL, LázaroE, GichI, ClarimónJ, Blanco-VacaF, BlesaR, Gómez-IslaT, LleóA (2008) Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord 26, 506-512.
37. Zhang W, Bai M, Xi Y, Hao J, Liu L, Mao N, Su C, Miao J, Li Z (2012) Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: Involvement of oxidative stress and cholinergic dysfunction. Free Radic Biol Med 52, 1443-1452.
38. Lopez OL (2011) The growing burden of Alzheimer's disease. Am J Manag Care 17, S339-S345.